A Post-Market Clinical Evaluation of the ReUnion TSA System

Sponsor
Stryker Trauma GmbH (Industry)
Overall Status
Terminated
CT.gov ID
NCT03858517
Collaborator
(none)
56
3
36.4
18.7
0.5

Study Details

Study Description

Brief Summary

This investigation is a prospective, multicenter clinical investigation. It is anticipated that a total of one hundred (100) subjects will be enrolled at approximately 4-7 sites. The clinical investigation has been designed to follow the surgeon's standard of care for joint arthroplasty subjects, which entails clinical evaluation on a regular ongoing basis, or as needed should the subject become symptomatic in the treated joint.

Condition or Disease Intervention/Treatment Phase
  • Device: ReUnion TSA System

Detailed Description

The objective of this clinical investigation is to demonstrate the safety and efficacy/performance of the ReUnion TSA System. Efficacy/performance of the procedure will be measured the American Shoulder and Elbow Surgeons (ASES) Shoulder Score. Safety of the ReUnion TSA System will be demonstrated through reporting of device-related intra-operative and post-operative Adverse Events (AEs). Enrolled subjects will be assessed at Pre-Operative, Operative/Discharge, and at 6 Weeks, 6 Months, 12 Months, 24 Months and annually thereafter up to 10 years following the index procedure.

Study Design

Study Type:
Observational
Actual Enrollment :
56 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Post-Market Clinical Evaluation of the ReUnion TSA System
Actual Study Start Date :
Jun 25, 2019
Actual Primary Completion Date :
Jul 8, 2022
Actual Study Completion Date :
Jul 8, 2022

Arms and Interventions

Arm Intervention/Treatment
ReUnion TSA System

Subject with one or more of the following diagnoses will be treated with the ReUnion TSA System: Aseptic necrosis of the humeral head Painful, disabling joint disease of the shoulder resulting from degenerative arthritis, rheumatoid arthritis or post-traumatic arthritis Failed previous total shoulder replacement, resurfacing or other procedure

Device: ReUnion TSA System
The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.

Outcome Measures

Primary Outcome Measures

  1. American Shoulder and Elbow Surgeons (ASES) Shoulder Score [24 months]

    The primary endpoint of the clinical investigation is to demonstrate non-inferiority of the device to the selected literature controls, as measured by the ASES Shoulder Score at 24 Months post-operative.

Secondary Outcome Measures

  1. Safety will be measured by capturing the incidence rate of device-related intra-operative and post-operative adverse events will be measured. [10 years]

    Secondary outcome measures to assess safety by capturing the incidence rate of device-related intra-operative adverse events.

  2. Efficacy will be measured by monitoring all implant survivorship in all subjects who have the total or partial prosthesis with full or partial implant survival. [10 years]

    Secondary outcome measures to assess efficacy by monitoring all implant survivorship in all subjects enrolled who have the ReUnion RFX System.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subject is willing to sign the informed consent.

  • Subject is willing and able to comply with postoperative scheduled clinical and radiographic evaluations.

  • Subject is male or non-pregnant female and 18 years or older at the time of surgery.

  • Subject has one or more of the following:

  • Aseptic necrosis of the humeral head

  • Painful, disabling joint disease of the shoulder resulting from degenerative arthritis, rheumatoid arthritis or post-traumatic arthritis

  • Failed previous total shoulder replacement, resurfacing or other procedure

Exclusion Criteria:
  • Subject has an active or suspected latent infection in or about the shoulder joint.

  • Subject has mental or neuromuscular disorder which would create an unacceptable risk of prosthesis instability, prosthesis fixation failure or complications in postoperative care.

  • Subject has bone stock compromised by disease, infection or prior implantation which cannot provide adequate support and/or fixation to the prosthesis.

  • Subject has anticipated activities which would impose high stresses on the prosthesis and its fixation.

  • Subject is obese such that he/she produces a load on the prosthesis which can lead to failure of fixation of the device or to failure of the device itself.

  • Subject has absent, irreparable or non-functioning rotator cuff and other essential muscles.

  • Subject has concomitant disease(s) which may significantly affect the clinical outcome.

  • Subject has traumatic or pathologic fracture of the proximal humerus.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Great Plains Orthopedics Peoria Illinois United States 61605
2 Tennessee Orthopaedic Alliance Nashville Michigan United States 37209
3 Steadman Hawkins Clinic of the Carolinas Greenville South Carolina United States 29615

Sponsors and Collaborators

  • Stryker Trauma GmbH

Investigators

  • Study Director: Rebecca Gibson, Stryker Trauma

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Stryker Trauma GmbH
ClinicalTrials.gov Identifier:
NCT03858517
Other Study ID Numbers:
  • ReUnion TSA Study
First Posted:
Feb 28, 2019
Last Update Posted:
Jul 26, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes

Study Results

No Results Posted as of Jul 26, 2022